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SuMMAry – in this study, galectin-3 was analyzed as a potential marker for preoperative detec-
tion of malignant thyroid lesions. Galectin-3 expression was analyzed by quantitative real-time reverse 
transcription polymerase chain reaction (rt-PCr) in preoperative thyroid fine-needle aspirates from 
245 patients with thyroid nodules. Out of 245 samples, 238 were adequate for analysis by rt-PCr. 
Galectin-3 was positive in 34 (89.5%) of 38 papillary carcinomas, 3 (89.5%) of 4 follicular carcinomas, 
17 (53.1%) of 32 follicular adenomas, 2 (33.3%) of 6 hurthle cell adenoma, 11 (28.2%) of 39 hashi-
moto thyroiditis, and 69 (57.9%) of 119 nodular goiter samples. Galectin-3 showed specificity of 
49.5%, sensitivity of 88.1%, positive predictive value of 27.2%, and negative predictive value of 95.1% 
as a marker for detection of malignant thyroid nodules. Owing to the relatively low positive predictive 
value due to the relatively high false positive rate, the clinical value of galectin-3 analyzed by quantita-
tive real-time rt-PCr as a marker for preoperative detection of malignant thyroid lesions is limited.
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Introduction
The standard method of preoperatively evaluating 
thyroid nodules regarding their potential malignancy 
is fine-needle aspiration (fnA) followed by cytologi-
cal analysis (1,2). A major limitation of fnA cytology 
is its inability to differentiate benign (hyperplasia and 
adenoma) from malignant (follicular carcinoma, fol-
licular variant of papillary carcinoma) follicular thy-
roid lesions (3). Most of the patients with such cyto-
logically indeterminate diagnosis are treated surgically 
by thyroidectomy to establish definitive pathological 
diagnosis. Thyroidectomy has a low but relevant mor-
bidity (injury of recurrent nerves and parathyroid 
glands) and requires life-long thyroid hormone re-
placement therapy. Since most of these patients are 
eventually classified as having benign lesions by pa-
thology, thyroidectomy can be considered an unavoid-
able over-treatment in these patients (4-6).
Many different markers have been studied with the 
aim of improving the accuracy of preoperative diagno-
sis of thyroid nodules and consequently avoiding un-
necessary thyroidectomies. These include extensive 
next-generation sequencing panels like the ThyroSeq 
test that analyses multiple genetic alterations in 112 
genes and multiple-gene expression tests like Affirma 
Gene expression Classifier that measures the expres-
sion of 167 genes (7-9). These panels are relatively ex-
pensive, and analysis of single gene expression has 
some advantages. Galectin-3 has shown the best re-
sults so far as a single marker analyzed by immunohis-
tochemistry and immunocytochemistry (10,11). Anal-
ysis of galectin-3 expression by reverse transcription 
polymerase chain reaction (rt-PCr) was performed 
in fewer studies with inconclusive results. in the larg-
est prospective study of galectin-3 by rt-PCr, it 
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showed high sensitivity and negative predictive value, 
but low specificity and positive predictive value as a 
marker for preoperative diagnosis of malignant thy-
roid lesions (12).
in this study, galectin-3 expression was analyzed by 
quantitative real-time PCr. We propose that quanti-
tative PCr analysis might improve diagnostic accura-
cy of galectin-3 compared with standard end-point 
PCr used in previous studies. 
Methods
Samples
This study included 245 patients with thyroid nod-
ules treated and followed at the department of Oncol-
ogy and nuclear Medicine, Sestre milosrdnice univer-
sity hospital Center. All the patients were evaluated 
by ultrasound-guided fnA as standard diagnostic 
procedure. Thyroid nodule fnA samples were col-
lected from patients by the cytopathologist using a 
25-G needle. After the aspirate was smeared for con-
ventional cytology, the leftover material in the needle 
was used for galectin-3 expression analysis. Only sam-
ples from patients with definitive postoperative histo-
pathologic diagnosis at the time of the conclusion of 
the study, from patients with definitive cytological di-
agnosis of nodular goiter, and from patients with de-
finitive preoperative diagnosis of hashimoto thyroid-
itis (based on cytology and high titer of antinuclear 
antibodies) were included in the study. The study was 
and performed in accordance with the declaration of 
helsinki ethical guidelines and approved by the ethi-
cal Committee of the Sestre milosrdnice university 
hospital Center (13).
RNA isolation, reverse transcription  
and real-time PCR
triPure isolation reagent (roche, indianapolis, 
in) was used for rnA isolation from fnA samples, 
according to the manufacturer’s instructions. reverse 
transcription was performed using a high Capacity 
cdnA reverse transcription Kit with rnase inhibi-
tor (Applied Biosystems, foster City, CA). The reac-
tion mixture consisting of 10 µl of isolated rnA and 
10 µl of 2x rt master mix was incubated in a ther-
mal cycler for 10 minutes at 25 °C, 120 minutes at 37 
°C, and a final 5 minutes at 85 °C. Obtained cdnA 
was stored at -20 °C until it was used for real-time 
PCr.
for real-time PCr reaction, the taqMan universal 
PCr Master Mix (Applied Biosystems) and taqMan 
Gene expression Assay, Assay id: hs00173587_m1 
(Applied Biosystems) for galectin-3 or taqMan en-
dogenous Control, human GAPd (GAPdh), fAM/
MGB (Applied Biosystems) for glyceraldehyde-
3-phosphate dehydrogenase (GAPdh) were used. 
The PCr reaction was performed in a final volume of 
25 µl with 4 µl cdnA in 7500 the real-time PCr 
System (Applied Biosystems). The setup for PCr re-
action was: 2 minutes at 52 °C, 10 minutes at 95 °C, 
and 45 cycles each consisting of 15 seconds at 95 °C 
and 1 minute at 60 °C. All samples were analyzed in 
duplicate. nontemplate control was included in each 
experiment.
The ΔΔCt method was used for the quantification 
of galectin-3 expression (14), with GAPdh analyzed 
as the endogenous control. A cdnA from healthy thy-
roid tissue was used as a calibrator sample for ΔΔCt 
quantification. to obtain that cdnA, thyroid tissues 
immediately after thyroidectomy were inspected by 
the pathologist who designated a healthy tissue por-
tion from which the fnA sample was obtained. rnA 
was isolated from fnA samples of healthy thyroid tis-
sue from 7 patients. These rnA isolates were pooled 
together and converted to cdnA by reverse transcrip-
tion, as described.
Statistical analysis
As galectin-3 relative expression values were not 
normally distributed tested using the Kolmogorov-
Smirnov test, whereas non-parametrical statistical 
tests were used for comparison between groups re-
garding galectin-3 expression: Mann-Whitney u test 
for two groups and Kruskal-Wallis test for more than 
two groups. When the Kruskal-Wallis test (p<0.05) 
was positive, post-hoc analysis with a test for pairwise 
comparison of subgroups was performed. receiver op-
erating characteristic (rOC) curve analysis was per-
formed to determine the cutoff value for galectin-3 
relative expression in discriminating between benign 
and malignant samples,. All samples with values above 
the cutoff value were regarded as positive. MedCalc 
version 10.4.0.0 (MedCalc Software bvba, Mariaker-
ke, Belgium) was used, and a p value of ≤0.05 was con-
sidered statistically significant.
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Results
Patients and samples
The study included 245 patients with thyroid nod-
ules, 47 (19%) men and 198 (81%) women. The age of 
patients ranged from 13 to 81 years, with a median age 
48 years. A preoperative fnA sample was taken from 
each of these patients and analyzed by real-time rt-
PCr for the expression of galectin-3.
Among 245 samples, 7 (3%) were inadequate for 
analysis due to no expression of the GAPdh control 
gene. Among 238 adequate samples, cytological diag-
nosis according to Bethesda classification was as fol-
lows: nondiagnostic or unsatisfactory in 4 (1.6%) sam-
ples, benign in 126 (52.9%) samples, atypia of unde-
termined significance in 19 (8.0%) samples, follicular 
neoplasm in 50 (21.0%) samples, suspicious for malig-
nancy in 13 (5.5%) samples, and malignant (papillary 
carcinoma) in 26 (10.9%) samples. Among 126 sam-
ples with benign cytological diagnosis, 81 were diag-
nosed by cytology as nodular goiter, 38 as hashimoto 
thyroiditis, and 7 as adenomatoid nodule.
Among 238 adequate samples, 115 (48%) were 
from patients with benign cytological diagnosis (79 
nodular goiters and 36 hashimoto thyroiditis) who 
did not have thyroid surgery during the course of the 
study. The remaining 123 (52%) samples were from 
patients that did undergo thyroid surgery. Postopera-
tive histopathological diagnoses for these samples 
were the following: papillary carcinoma in 38 samples, 
follicular carcinoma in 4 samples, follicular adenoma 
in 32 samples, hurthle cell adenoma in 6 samples, and 
nodular goiter in 43 samples. The association between 
preoperative cytological diagnosis and postoperative 
histopathological diagnosis is shown in table 1.
Galectin-3 expression
Galectin-3 gene expression was studied using real-
time rt-PCr. A significant difference in galectin-3 
expression was found between groups of patients with 
different final diagnosis (Kruskal-Wallis test, 
p<0.0001). Post hoc pairwise comparison statistical 
analysis showed a significant difference in galectin-3 
expression between the group with final diagnosis of 
papillary carcinoma and all groups with benign final 
diagnosis. furthermore, a significant difference was 
found between groups with final diagnosis of hashi-
moto thyroiditis and follicular adenoma and hashi-
moto thyroiditis and nodular goiter. no significant 
difference in galectin-3 expression was found between 
other pairs of groups of patients regarding their final 
diagnosis. The final diagnosis of hashimoto thyroiditis 
was based on preoperative fnA cytological analysis 
and high titer of antinuclear antibodies. The final diag-
nosis of nodular goiter was based either on postopera-
tive histopathological analysis or on preoperative fnA 
cytological analysis in patients in which surgery was 
not performed. All other final diagnoses (papillary car-
cinoma, follicular carcinoma, follicular adenoma, and 
hurthle cell adenoma) were based on postoperative 
histopathological analysis.
Table 1. Distribution of 238 patients with samples adequate for RT-PCR regarding postoperative histopathological 









for malignancy Malignant total
Papillary carcinoma 0 0 2 0 10 26 38
follicular carcinoma 0 0 0 3 1 0 4
follicular adenoma 0 3 7 22 0 0 32
hurthle cell adenoma 0 2 2 2 0 0 6
nodular goiter 4 6 8 23 2 0 43
not availablea 0 115 0 0 0 0 115
All 4 126 19 50 13 26 238
* rt-PCr, reverse transcriptase polymerase chain reaction; AuS, atypia of undetermined significance; a patients did not undergo surgery 
because definitive preoperative diagnosis of nodular goiter (in 79 patients) or hashimoto thyroiditis (in 36 patients) was established
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Median galectin-3 gene expression was 2.5 (inter-
quartile range (iQr): 1.8-4.4) in patients with malig-
nant final diagnosis and 1.3 (iQr: 0.4-2.9) in patients 
with benign final diagnosis. The difference in galec-
tin-3 gene expression between these groups was statis-
tically significant (Mann-Whitney u test, z=3.6736, 
p=0.0002) (figure 1). There was also a difference in 
galectin-3 gene expression between patients with ma-
lignant final diagnosis and patients with follicular ad-
enoma final diagnosis (median = 1.4, iQr= 0.6 to 2.3) 
that was statistically significant (Mann-Whitney u 
test, z=3.4299, p=0.0006).
difference in galectin-3 expression was analyzed in 
a subgroup of patients with unsatisfactory cytological 
diagnosis or indeterminate cytological diagnosis re-
garding malignancy according to Bethesda classifica-
tion. in this subgroup of patients, there was also a dif-
ference in galectin-3 gene expression between patients 
with malignant (median = 2.5, iQr =1.8 to 4.9) and 
benign final diagnosis (median = 1.3, iQr= 0.6 to 2.7) 
that was statistically significant (Mann-Whitney u 
test, z=2.508, p=0.01).
Figure 1. Galectin-3 gene expression in preoperative 
fine-needle aspiration samples of thyroid nodules with 
malignant and benign final diagnosis.
Figure 2. Receiver-operating curve analysis of galectin-3 
expression in preoperative fine-needle aspiration samples 
of thyroid nodules as a marker to discriminate malignant 
from benign thyroid nodules.
Table 2. Galectin-3 gene expression detected by real-time 
RT-PCR in preoperative fine-needle aspiration samples 








or unsatisfactory 3 (0.8%) 4
Benign 63 (50.0%) 126
AuS 13 (68.4%) 19
follicular neoplasm 25 (50.0%) 50
Suspicious  
for malignancy 9 (69.2%) 13
Malignant 23 (88.4%) 26
All 136 (57.1%) 238
*AuS, atypia of undetermined significance
Table 3. Galectin-3 gene expression detected by real-time 
RT-PCR in preoperative fine-needle aspiration samples 







Papillary carcinomaa 34 (89.5%) 38
follicular carcinomaa 3 (75.0%) 4
follicular adenomaa 17 (53.1%) 32
hurthle cell adenomaa 2 (33.3%) 6
hashimoto thyroiditisb 11 (28.2%) 39
nodular goiterc 69 (57.9%) 119
All 136 (57.1%) 238
a diagnosis was established postoperatively by histopathological 
analysis; b diagnosis was established preoperatively based on fnA 
cytology and high titer of anti-nuclear antibodies; c diagnosis was 
established either preoperatively by fnA cytology or postopera-
tively by histopathological analysis
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Galectin-3 diagnostic value
rOC curve analysis was performed to assess the 
value of galectin-3 gene expression in discriminating 
between benign and malignant thyroid nodules (fig-
ure 2). The area under the rOC curve was 0.681 (95% 
confidence interval (Ci) 0.617-0.739). using rOC 
curve analysis, the optimal cutoff value for galectin-3 
relative gene expression was set at 1.16. With this cut-
off value, galectin-3 showed a specificity of 49.5% 
(95% Ci 42.3-56.7%), sensitivity of 88.1% (95% Ci 
74.4-96.0%), positive predictive value of 27.2% (95% 
Ci 19.9-35.5%), and negative predictive value of 
95.1% (95% Ci 88.9-98.4%).
All samples with galectin-3 expression above the 
cutoff value were considered positive. The number 
of positive samples for each cytological diagnosis and 
for each final diagnosis are presented in table 2 and 
table 3.
Discussion
Galectin-3 is a lectin, a member of the beta-galac-
toside binding protein family that plays a role in dif-
ferent cellular functions that are related to malignant 
transformation such as cellular adhesion, migration, 
growth, differentiation, and apoptosis (15). tt has 
therefore been studied as a potential marker for cancer 
diagnosis, particularly for thyroid cancer (16). The 
clinically most relevant application of this marker 
would be as an ancillary method to fnA cytology to 
establish accurate preoperative diagnosis of thyroid 
nodules with indeterminate cytological diagnosis re-
garding malignancy. Many studies have shown selec-
tive expression of galectin-3 in malignant thyroid le-
sions compared with healthy thyroid tissue and benign 
lesions (17-20). in the largest multicenter study on 
1006 thyroid lesions, immunohistochemical analysis 
of galectin-3 showed specificity, sensitivity, positive 
predictive value, and diagnostic accuracy in detecting 
malignant lesions of 88%, 98%, 91%, and 97%, respec-
tively (21). in the largest prospective multicenter study 
in which galectin-3 was evaluated preoperatively on 
fnA samples from patients with indeterminate cyto-
logical diagnosis, it showed a specificity of 93% and 
sensitivity of 78% in discriminating benign from ma-
lignant lesions (22).
unlike most of studies in which galectin-3 expres-
sion was evaluated on the protein level using immuno-
chemistry, in our study galectin-3 expression was ana-
lysed on the mrnA level using quantitative real-time 
rt-PCr. The major advantage of rt-PCr compared 
with immunochemistry is that interpretation of the 
results does not depend on the subjective evaluation by 
a trained cytologist.
We have found significantly higher expression of 
galectin-3 in samples from malignant lesions com-
pared with benign lesions. however, the diagnostic ac-
curacy of galectin-3 in our study was limited, with a 
specificity of 50%, sensitivity of 88%, positive predic-
tive value of 27%, and negative predictive value of 95%. 
The limited diagnostic accuracy shown in this study, 
mostly due to a high false positive rate, is in accordance 
with previous rt-PCr studies of galectin-3 expres-
sion in preoperative thyroid fnA samples (12,23-26). 
The high false positive rate of galectin-3 expression 
detected by PCr might be due to galectin-3 expres-
sion in other cells present in thyroid fnA samples in 
addition to thyroid epithelium cells. it has been shown 
that galectin-3 expression in hashimoto thyroiditis 
samples might be due to presence of hurthle cells that 
are known to express galectin-3 (27,28). This indicates 
that immunochemical analysis has an advantage com-
pared with rt-PCr analysis of galectin-3 expression 
because immunochemistry enables morphological dis-
tinction of types of cells expressing galectin-3 in fnA 
samples.
The hypothesis of the present study was that quan-
titative real-time PCr used in this study has better 
diagnostic accuracy compared with end-point PCr 
used in previous studies of galectin-3 in preoperative 
fnA samples from thyroid nodules. it was previously 
shown that real-time PCr has higher sensitivity, dy-
namic range, and precision than end-point PCr (29). 
We did not confirm this hypothesis, finding similar 
limited diagnostic accuracy as shown previously by 
end-point PCr (12). The reason is that the high false 
positive rate is due to biology of thyroid, namely ex-
pression of galectin-3 in other cells as discussed previ-
ously, and not due to the limitations of the method.
The number of samples from patients with follicu-
lar thyroid carcinoma was small in our study, which 
represents a limitation. incidence of follicular carci-
noma is low in Croatia, probably due to complete io-
dine intake sufficiency, and this study was performed 
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on an unselected group of patients with thyroid nod-
ules, so we could not increase the proportion of pa-
tients with follicular thyroid carcinoma (30).
in conclusion, our study has shown that quantita-
tive real-time rt-PCr analysis of galectin-3 expres-
sion has limited clinical value in preoperative diagnosis 
of malignant thyroid nodules, mostly due to low posi-
tive predictive value.
References
 1. Gharib h, Goellner Jr. fine-needle aspiration biopsy of thet-
hyroid: an appraisal. Ann intern Med. 1993;118:282–289.
 2. Baloch ZW, livolsi vA. fine-needle aspiration of thyroid 
nodules:past, present, and future. endocr Pract. 2004;10: 
234–241.
 3. Carpi A, nicolini A, Gross Md, et al. Controversies in diag-
nosticapproaches to the indeterminate follicular thyroid nod-
ule.Biomed Pharmacother. 2005;59:517–520.
 4. Kim eS, nam-Goong iS, Gong G, et al. Postoperative findings 
and risk for malignancy in thyroid nodules with cytological di-
agnosis of the so-called “follicular neoplasms”. Korean J intern 
Med. 2003;18:94–97.
 5. Sorrenti S, trimboli P, Catania A et al. Comparison of malig-
nancy rate in thyroid nodules with cytology of indeterminate 
follicular or indeterminate hurthle cell neoplasm. Thyroid. 
2009;19, 355–360.
 6. Asari r, niederle Be, Scheuba C et al. indeterminate thyroid 
nodules: A challenge for the surgical strategy. Surgery. 2010; 
148, 516–525.
 7. rossi ed, Pantanowitz l, faquin WC. The role of Molecular 
testing for the indeterminate Thyroid fnA. Genes (Basel). 
2019;10(10):736.
 8. nikiforova Mn, Mercurio S, Wald Ai, et al. Analytical perfor-
mance of the ThyroSeq v3 genomic classifier for cancer diagno-
sis in thyroid nodules. Cancer. 2018;124(8):1682‐1690.
 9. Jug rC, datto MB, Jiang xS. Molecular testing for indetermi-
nate thyroid nodules: Performance of the Afirma gene expres-
sion classifier and ThyroSeq panel. Cancer Cytopathol. 2018; 
126(7):471‐480.
10. Griffith Ol, Chiu CG, Gown AM, Jones SJ, Wiseman SM. 
Biomarker panel diagnosis of thyroid cancer: a critical review. 
expert rev Anticancer Ther. 2008;8(9):1399‐1413.
11. Chiu CG, Strugnell SS, Griffith Ol, et al. diagnostic utility of 
galectin-3 in thyroid cancer. Am J Pathol. 2010;176(5): 
2067‐2081.
12. Šamija i, Mateša n, lukač J, Kusić Z. Galectin-3 and Cd44v6 
as markers for preoperative diagnosis of thyroid cancer by 
rt-PCr. diagn Mol Pathol. 2011;20(4):233‐241.
13. World Medical Association. World Medical Association dec-
laration of helsinki: ethical principles for medical research in-
volving human subjects. JAMA. 2013;310(20):2191‐2194.
14. livak KJ, Schmittgen td. Analysis of relative gene expression 
data using real-time quantitative PCr and the 2(-delta delta 
C(t)) Method. Methods. 2001;25(4):402‐408.
15. Wang l, Guo x-l. Molecular regulation of galectin-3 expres-
sion andtherapeutic implication in cancer progression. Biomed 
Pharmacother. 2016;78:165–171.
16. trimboli P, virili C, romanelli f, Crescenzi A, Giovanella l. 
Galectin-3 Performance in histologic a Cytologic Assessment 
of Thyroid nodules: A Systematic review and Meta-Analysis. 
int J Mol Sci. 2017;18(8):1756.
17. Sanabria A, Carvalho Al, Piana de Andrade v, et al. is galec-
tin-3 a good method for the detection of malignancy in pa-
tients with thyroid nodules and a cytologic diagnosis of “fol-
licular neoplasm”? A critical appraisal of the evidence. head 
neck. 2007;29(11):1046‐1054.
18. Gasbarri A, Martegani MP, del Prete f, lucante t, natali PG, 
Bartolazzi A. Galectin-3 and Cd44v6 isoforms in the preop-
erative evaluation of thyroid nodules. J Clin Oncol. 1999;17 
(11):3494‐3502.
19. Papotti M, rodriguez J, de Pompa r, Bartolazzi A, rosai J. 
Galectin-3 and hBMe-1 expression in well-differentiated 
thyroid tumors with follicular architecture of uncertain malig-
nant potential. Mod Pathol. 2005;18(4):541‐546.
20. Carpi A, rossi G, Coscio Gd, et al. Galectin-3 detection on 
large-needle aspiration biopsy improves preoperative selection 
of thyroid nodules: a prospective cohort study. Ann Med. 
2010;42(1):70‐78.
21. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an 
immunodiagnostic method for improving preoperative diagno-
sis of nodular thyroid lesions. lancet. 2001;357(9269):1644‐1650.
22. Bartolazzi A, Orlandi f, Saggiorato e, et al. Galectin-3-expres-
sion analysis in the surgical selection of follicular thyroid nod-
ules with indeterminate fine-needle aspiration cytology: a pro-
spective multicentre study. lancet Oncol. 2008;9(6):543‐549.
23. Pineda P, rojas P, liberman C, et al. detection of malignancy-
markers in thyroid nodules by reverse transcriptase poly-
merasechain reaction (rt-PCr). rev Med Chil. 2003;131: 
965–972.
24. Pagedar nA, Chen dh, Wasman JK, et al. Molecular classifi-
cationof thyroid nodules by cytology. laryngoscope. 2008;118: 
692–696.
25. Aratake y, umeki K, Kiyoyama K, et al. diagnostic utility of-
galectin-3 and Cd26/dPPiv as preoperative diagnostic mar-
kers forthyroid nodules. diagn Cytopathol. 2002;26:366–372.
26. Martins l, Matsuo Se, ebina Kn, et al. Galectin-3 messen-
gerribonucleic acid and protein are expressed in benign thyroid 
tumors. J Clin endocrinol Metab. 2002;87:4806–4810.
27. niedziela M, Maceluch J, Korman e. Galectin-3 is not an 
 universalmarker of malignancy in thyroid nodular disease in 
children andadolescents. J Clin endocrinol Metab. 2002;87: 
4411–4415.
28. Matesa n, Samija i, Kusic Z. Galectin-3 and Cd44v6 positiv-
ity byrt-PCr method in fine needle aspirates of benign thy-
roid lesions. Cytopathology. 2007;18:112–116.
I. Šamija et al. Galectin-3 in thyroid nodules
Acta Clin Croat, Vol. 59, (Suppl. 1) 2020 31
29. Gál AB, Carnwath JW, dinnyes A, herrmann d, niemann h, 
Wrenzycki C. Comparison of real-time polymerase chain reac-
tion and end-point polymerase chain reaction for the analysis 
of gene expression in preimplantation embryos. reprod fertil 
dev. 2006;18(3):365‐371.
30. Kusić Z, novosel SA, dabelić n, et al. Croatia has reached io-
dinesufficiency. J endocrinol invest. 2003;26:738–742.
Sažetak
Kvantitativna analiza ekspresije galektina-3 u benignim i malignim čvorovima štitnjače
I. Šamija, N. Mateša, S. Tadinac i T. Jukić
u ovom istraživanju galektin-3 je istraživan kao potencijalni biljeg za predoperativnu detekciju malignih lezija štitnjače. 
ekspresija galektina-3 je analizirana kvantitativnom lančanom reakcijom polimerazom nakon reverzne transkripcije 
(rt-PCr) u stvarnom vremenu u predoperativnim aspiratima tankom iglom 245 bolesnika s čvorovima štitnjače. uzorci 
238 bolesnika od ukupno 245 su se pokazali adekvatnima za rt-PCr analizu. Galektin-3 je bio pozitivan u 34 (89.5%) od 
38 uzoraka papilarnog karcinoma, 3 (89.5%) od 4 uzorka folikularnog karcinoma, 17 (53.1%) od 32 uzorka folikularnog 
adenoma, 2 (33.3%) od 6 uzoraka adenoma hurthleovih stanica, 11 (28.2%) od 39 uzoraka hashimotovog tiroiditisa i 69 
(57.9%) od 119 uzoraka nodularne strume. Kao biljeg za razlikovanje malignih od benignih čvorova štitnjače, galektin-3 je 
pokazao specifičnost od 49.5%, osjetljivost od 88.1%, pozitivnu prediktivnu vrijednost od 27.2% i negativnu prediktivnu 
vrijednost od 95.1%. Zbog relativno niske pozitivne prediktivne vrijednosti uslijed relativno velikog broja lažno pozitivnih 
rezultata, klinička vrijednost određivanja galektina-3 kvantitativnim rt-PCr-om u stvarnom vremenu kao biljega za pred-
operativnu detekciju malignih čvorova štitnjače je ograničena. 
Ključne riječi: čvor u štitnjači, lančana reakcija polimerazom nakon reverzne transkripcije, rak štitnjače, biopsija tankom iglom
